Description
Balicatib is an inhibitor of cathepsin K that displays anti-resorptive activity. Balicatib inhibits osteoclast activity, decreasing bone turnover and increasing bone mineral density and bone formation rates.
Balicatib
Product ID B0245
Cas No. 354813-19-7
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 354813-19-7 |
|---|---|
| Purity | ≥98% |
| Formula | C23H33N5O2 |
| Formula Wt. | 411.55 |
| IUPAC Name | N-{1-[(Cyanomethyl)carbamoyl]cyclohexyl}-4-(4-propyl-1-piperazinyl)benzamide |
| Synonym | AAE-581 |
| Solubility | DMSO: ≥ 46 mg/mL |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Jerome C, Missbach M, Gamse R. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int. 2012 Jan;23(1):339-49. PMID: 21380636.
Chappard D, Libouban H, Mindeholm L, et al. The cathepsin K inhibitor AAE581 induces morphological changes in osteoclasts of treated patients. Microsc Res Tech. 2010 Jul;73(7):726-32. PMID: 20025055.